{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:45:57Z","timestamp":1782798357559,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.vaccine.2015.12.066","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T10:37:30Z","timestamp":1452249450000},"page":"1077-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2\u20136 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands"],"prefix":"10.1016","volume":"34","author":[{"given":"Gertjan H.J.","family":"Wagenvoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Vlaminckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Elberse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2015.12.066_bib0195","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/infdis\/jis240","article-title":"Aging population and future burden of pneumococcal pneumonia in the United States","volume":"205","author":"Wroe","year":"2012","journal-title":"J Infect Dis"},{"issue":"9693","key":"10.1016\/j.vaccine.2015.12.066_bib0200","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2015.12.066_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.066_bib0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijmm.2009.05.005","article-title":"Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states","volume":"300","author":"Imohl","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.12.066_bib0215","series-title":"RIVM rapport 201001001","article-title":"Vaccinatiegraad Rijksvaccinatieprogramma Nederland: Verslagjaar 2012","author":"van Lier","year":"2012"},{"issue":"26","key":"10.1016\/j.vaccine.2015.12.066_bib0220","first-page":"1454","article-title":"Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk","volume":"151","author":"de Greeff","year":"2007","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"10.1016\/j.vaccine.2015.12.066_bib0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12325-013-0007-6","article-title":"The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review","volume":"30","author":"Myint","year":"2013","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.066_bib0230","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid1811.120329","article-title":"Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands","volume":"18","author":"van Deursen","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.066_bib0235","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/thx.53.3.159","article-title":"Pneumococcal serotypes and their clinical relevance","volume":"53","author":"Kalin","year":"1998","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.vaccine.2015.12.066_bib0240","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1128\/IAI.00724-13","article-title":"Surface charge of Streptococcus pneumoniae predicts serotype distribution","volume":"81","author":"Li","year":"2013","journal-title":"Infect Immun"},{"issue":"21","key":"10.1016\/j.vaccine.2015.12.066_bib0245","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","article-title":"Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults","volume":"32","author":"Grabenstein","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.066_bib0250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.12.066_bib0255","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.12.066_bib0260","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/600045","article-title":"Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome","volume":"49","author":"Jansen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.12.066_bib0265","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3201\/eid1605.091223","article-title":"Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands","volume":"16","author":"Rodenburg","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.12.066_bib0270","series-title":"Modern epidemiology","first-page":"258","article-title":"Chapter 15 Introduction to stratified analysis","author":"Rothman","year":"2008"},{"issue":"8","key":"10.1016\/j.vaccine.2015.12.066_bib0275","doi-asserted-by":"crossref","first-page":"e42595","DOI":"10.1371\/journal.pone.0042595","article-title":"Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306","volume":"7","author":"Grau","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.066_bib0280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCP.0b013e3283606ab5","article-title":"The increasing incidence of empyema","volume":"19","author":"Burgos","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.12.066_bib0285","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3201\/eid1609.100102","article-title":"Pneumococcal serotypes in children in 4 European countries","volume":"16","author":"Hanquet","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.066_bib0290","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-014-2062-6","article-title":"Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology","volume":"33","author":"Fletcher","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2015.12.066_bib0295","doi-asserted-by":"crossref","first-page":"874189","DOI":"10.1155\/2010\/874189","article-title":"Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992\u20132008)","volume":"2010","author":"Imohl","year":"2010","journal-title":"Int J Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.12.066_bib0300","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.066_bib0305","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1086\/592970","article-title":"Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995\u20132007: a population-based study","volume":"47","author":"Tsigrelis","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2015.12.066_bib0310","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","article-title":"Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995\u20132011","volume":"31","author":"Rudnick","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.066_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc1876","article-title":"The Surviving Sepsis Campaign: raising awareness to reduce mortality","volume":"7","author":"Slade","year":"2003","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.vaccine.2015.12.066_bib0320","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1471-0528.2011.03010.x","article-title":"Trends in preterm birth: singleton and multiple pregnancies in the Netherlands, 2000\u20132007","volume":"118","author":"Schaaf","year":"2011","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.066_bib0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1469-0691.2012.03895.x","article-title":"Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia","volume":"19","author":"Burgos","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.vaccine.2015.12.066_bib0330","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinternmed.2010.53","article-title":"Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era","volume":"170","author":"Metlay","year":"2010","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.066_bib0335","doi-asserted-by":"crossref","first-page":"e39150","DOI":"10.1371\/journal.pone.0039150","article-title":"Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes","volume":"7","author":"van Hoek","year":"2012","journal-title":"PLoS ONE"},{"issue":"16","key":"10.1016\/j.vaccine.2015.12.066_bib0340","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.066_bib0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/499242","article-title":"Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen","volume":"42","author":"Sjostrom","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.066_bib0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1183\/09031936.00144712","article-title":"Serotypes associated with the development of pneumococcal para-pneumonic effusion in adults","volume":"42","author":"Bewick","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.066_bib0355","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3201\/eid2103.140634","article-title":"Risk factors for death from invasive pneumococcal disease, Europe, 2010","volume":"21","author":"Navarro-Torne","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.066_bib0360","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1183\/09031936.00080814","article-title":"Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types","volume":"44","author":"Browall","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.066_bib0365","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1901.120741","article-title":"Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales","volume":"19","author":"Ladhani","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.12.066_bib0370","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jama.2010.1290","article-title":"Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains","volume":"304","author":"van Gils","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.066_bib0375","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3201\/eid2111.140780","article-title":"Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands","volume":"21","author":"Knol","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.12.066_bib0380","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T04:53:43Z","timestamp":1537073623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0264410X16000037"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2\u20136 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}